Abcam is pleased to announce it has entered into an agreement to acquire MitoSciences Inc. a leading provider of cutting edge mitochondrial research tools. This represents a further step towards Abcam’s mission of becoming the leading supplier of protein research and detection tools.
MitoSciences has over 200 products in the areas of metabolism and apoptosis, including antibody cocktails, sandwich ELISA kits, in-cell ELISA, flow cytometry antibodies and enzyme activity assays. The acquisition enhances Abcam’s existing portfolio in these areas and complements an increasing range of non-antibody products. The MitoSciences product range will be available via Abcam’s website and authorized distributors within six weeks. Products will carry the MitoSciences logo.
Jonathan Milner, Chief Executive of Abcam said:
“The combined companies will be the market leader in mitochondrial research and will extend our in-house manufacturing and product development capabilities in the exciting area of immunoassay platforms.
“We remain committed to providing customers with the highest quality products available and will continue to deliver MitoSciences’ excellence in product performance and customer support.
“We are delighted to have this opportunity to extend our product offering to customers and strengthen our business in this research area. We look forward to welcoming the employees of MitoSciences into the Abcam team and aim for a smooth transition for existing customers.”
MitoSciences was a privately held biotech company based in Eugene, Oregon (US). The Company produce and distribute immunoassay platforms and high performance monoclonal antibodies. It was founded in 2004 with the mission of advancing mitochondrial research and developing products that support critical research in cancer, neurodegeneration and metabolic disorders.
For further information contact:
Abcam +44 (0) 1223 696000
MitoSciences + 1 541 284 1800